Abstract. For a successful repair and reconstruction of bladder tissue, fabrication of sca olds with proper biochemical and biomechanical characteristics is necessary. Decellularized bladder tissue has been proposed in previous studies as a gold standard material for sca old fabrication. However, weak mechanical properties of such a loadbearing tissue has remained a challenge. Incorporation of both biological and synthetic materials has been known as an e ective strategy for improving mechanical and biological properties of the sca olds. In the present work, a simple process was developed to fabricate hybrid hydrogel sca olds with a biomimetic architecture from the natural urinary bladder extracellular matrix (ECM) and synthetic polycaprolactone (PCL) nano bers in order to obtain a sca old with optimized mechanical and biological properties for bladder tissue engineering. To this end, the ECM gel was derived from rat bladder, and the electrospun PCL nano bers were embedded within the gel, followed by incubating the composite to shape the hybrid hydrogel. These reinforced sca olds showed more structural integrity and mechanical stability. The introduced concept of nano ber-reinforced ECM can be applied as a promising platform in engineering of bladder or other load-bearing soft tissues.
Introduction
In 1993, Langer and Vacanti highlighted tissue engineering from previous studies to describe a new interdisciplinary eld that employs engineering rules toward the evolution of biological substitutes [1] . Nearly 25 years later, many advances have been made with regard to a wide range of tissues and organs, recently reviewed by Langer and Vacanti [2] . Tissue engineering relies on the body's natural ability to regenerate. The two tissue engineering strategies, i.e. sca old alone or cell seeded matrices, have been studied in the bladder tissue engineering [3] .
Structure and function of the bladder are simpler than those of complex organs are such as kidney and heart. The primary function of bladder as a part of the urinary system in body is to store and remove urine [4] . When this reservoir operates properly, high capacity is maintained and low pressure is kept; it also protects the upper urinary track from any pressure and other damages [3] . Some conditions can widely lead to bladder dysfunction including cancer, infection, trauma, neurological control disorders, and congenital disorders [4] . These conditions require suitable reconstructive procedures that can be performed with heterologous or non-heterologous tissues or arti cial materials. Gastrointestinal segments are used mostly in these bladder reconstruction procedures [5] ; however, incorporation of these tissues into urinary systems can cause several complications such as urolithiasis, metabolic disturbances, increased mucous production, and malignant disease [6] . These problems have led to advanced research into bladder tissue engineering [7] .
By means of tissue engineering approach, many innovative methods have been developed for bladder reconstruction di ering in biomaterials, cells, and growth factors [8] . Generally, three main strategies have been used in bladder tissue engineering for the fabrication of arti cial bladder tissue or entire bladders, including engineering entire, partial or patch structures for further applications [4] . In 2001, Atala successfully implanted a canine bladder as the rst tissue engineered organ in human [9] that is a proven document for probable results of tissue engineering approaches in the regeneration of bladder tissue or in the construction of arti cial bladder [8] . Here, we have employed the second strategy to fabricate a cell-free gel-patch sca old, which is more prone to commercialization and translation to clinic.
Biomaterials in the bladder tissue engineering are biological materials, such as acellular tissue matrices [10, 11] , derived from natural sources or synthetic polymers, such as polycaprolacton (PCL) [7, 12] , using various fabrication techniques such as electrospinning, solvent casting, particulate leaching, 3D printing, gas foaming, phase separation, and freeze drying [9, [13] [14] [15] [16] . Incorporation of both biological and synthetic materials along with the goal of reinforcing matrices' mechanical properties and optimizing biological properties has been proposed in previous studies [12] .
In this study, a simple process is developed to fabricate hybrid hydrogel sca olds with a well-de ned architecture from the urinary bladder matrix and PCL nano bers. These reinforced sca olds showed better mechanical properties, proposing a promising approach to regenerative medicine and tissue engineering applications.
Materials and method 2.1. Decellularization of rat bladder tissue
Rat bladder tissues were decellularized, as previously described [11] . In brief, rat bladder tissue slices were washed with Dulbecco's Phosphate-Bu ered Saline (PBS) and Sodium Dodecyl Sulfate (SDS, 1% w/v) for 24 h. The tissue was nally treated with a nuclease solution, and then washed in sterile PBS. Histological and DNA analyses were performed for test and control groups.
Preparation of bladder-derived gel
Milled acellular bladder powder was allowed to digest in pepsin at 17 mg/ml that was dissolved in 0.5 M acetic acid for about 72 h under constant stirring. Then, the solution was brought to pH 7.4 by the addition of 1 M NaOH and 10X PBS, forming a viscous gel solution.
Electrospinning PCL nano bers
The polymer solution with concentration of 12 wt.% in Chloroform and Methanol (3:1) was prepared by continuous stirring to dissolve pelletized PCL. The solution was placed in a 10 cc syringe with a 20-gauge blunt tip needle and electrospun using a high-voltage DC power supply set to 17 kV, a 15 cm tip-to-substrate distance, and a 1.5 ml/h ow rate. The optimized processing parameters are summarized in Table 1 .
Fabrication of hybrid composite
A simple process was developed to generate hybrid hydrogel sca olds with a well-de ned architecture from urinary bladder matrix and PCL nano ber mat (Figure 1) . At rst, a layer of gel solution (0.6 ml) was incubated in a small cylinder (1 cm diameter) that shaped the gel for 10 min, and then we put a nano ber mat on the semi-cured gel; next, the second layer of the gel (0.4 ml) was injected into the cylinder for 15 min of incubation. De nite amount of solution (1 ml) was injected into the cylinder and incubated with or without PCL mat for test and control group, respectively.
Results and discussion
Here, we demonstrated the complete removal (> 99%) of cellular contents through SDS decellularization protocol. By using this mild technique, native tissue components, which play pivotal roles in original ECM construct, have been thoroughly preserves [17] . Histologic analysis of native bladder showed no evidence of intact nuclear material on H&E staining as compared to native bladder (Figure 2(a) ). As shown by MT stain- ing, the overall matrix histoarchitecture and major structural components, i.e. collagen, remained intact. To determine the presence of decellularized tissue (DCbaldder), DNA measurement was performed.
After decellularization, there was a 36 12 ng DNA/mg wet weight compared to the 7600 600 ng DNA/mg wet weight found in native bladder tissue (Figure 2(b) ).
Although the mechanical properties of the reinforced hybrid hydrogels were weaker than those urinary bladder tissues, the enhancement brought by electrospun PCL bers was considerable (Figure 3) . Not only the mechanical properties of hydrogel improved, but also handling of this sca old was promoted during suturing. We found that further mechanical testing is not essential in our study and reinforcement can be observed with naked eye (Figure 3) . Hybrid hydrogel/PCL sca old exhibited a range of biological and mechanically tunable pro les. Thus, these sca olds have the potential to meet an assortment of cellular and mechanical demands required for engineering tissues.
Conclusion
We successfully fabricated a 3D hybrid hydrogel/PCL with biomimetic properties for urinary tissue engineering. It can be a good candidate and a promising approach in regenerative medicine. 
